Additional Relevant Details Raptor Pharmaceuticals announced the FDA has granted Qualified Infectious Disease Product (QIDP) designation to MP-376, the company's proprietary inhaled levofloxacin, for three distinct indications: for the treatment of chronic pulmonary infections due toPseudomonas aeruginosa, in patients with cystic fibrosis (CF) and in patients with non-cystic fibrosis bronchiectasis (BE), and in patients with nontuberculous mycobacteria (NTM).  The designations "provides Raptor with significant incentives for the development of MP-376, including priority review by the FDA, eligibility for Fast Track designation and a five-year extension of marketing exclusivity under the Hatch-Waxman Act."